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Essential hypertension is a common disease, yet its pathogenesis is
not well understood. Altered control of sodium excretion in the
kidney may be a key causative feature, but this has been difficult
to test experimentally, and recent studies have challenged this
hypothesis. Based on the critical role of the renin-angiotensin
system (RAS) and the type I (AT1) angiotensin receptor in essential
hypertension, we developed an experimental model to separate
AT1 receptor pools in the kidney from those in all other tissues.
Although actions of the RAS in a variety of target organs have the
potential to promote high blood pressure and end-organ damage,
we show here that angiotensin II causes hypertension primarily
through effects on AT1 receptors in the kidney. We find that renal
AT1 receptors are absolutely required for the development of
angiotensin II-dependent hypertension and cardiac hypertrophy.
When AT1 receptors are eliminated from the kidney, the residual
repertoire of systemic, extrarenal AT1 receptors is not sufficient to
induce hypertension or cardiac hypertrophy. Our findings demon-
strate the critical role of the kidney in the pathogenesis of hyper-
tension and its cardiovascular complications. Further, they suggest
that the major mechanism of action of RAS inhibitors in hyperten-
sion is attenuation of angiotensin II effects in the kidney.
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H igh blood pressure (BP) is a highly prevalent disorder, and itscomplications (including heart disease, stroke, and kidney
disease) are a major public health problem (1). Despite decades of
scrutiny, the precise pathogenesis of essential hypertension has
been difficult to delineate. Guyton and his associates suggested that
defective handling of sodium by the kidney and consequent dys-
regulation of body fluid volumes is a requisite, final common
pathway in hypertension pathogenesis (2). The powerful capacity of
this pathway to modulate blood pressure is illustrated by the elegant
studies of Lifton and associates showing that virtually all of the
Mendelian disorders with major impact on blood pressure ho-
meostasis are caused by genetic variants affecting salt and water
reabsorption by the distal nephron (3). On the other hand, several
recent studies have suggested that primary vascular defects may
cause hypertension by impacting peripheral resistance without
direct involvement of renal excretory functions (4–7).
Among the various regulatory systems that impact blood pres-
sure, the RAS has a key role. Inappropriate activation of the RAS,
as in renal artery stenosis, leads to profound hypertension and
cardiovascular morbidity (8). Moreover, in patients with essential
hypertension who typically lack overt signs of RAS activation, ACE
inhibitors and angiotensin receptor blockers (ARBs) effectively
reduce blood pressure and ameliorate cardiovascular complications
(9–11), suggesting that dysregulation of the RAS contributes to
their elevated blood pressure.
At the cellular level, responsiveness to angiotensin II (Ang
II) is conferred by the expression of the two classes of
angiotensin receptors (AT1 and AT2). The effects of Ang II to
increase blood pressure are mediated by AT1 receptors (12),
and these receptors are expressed in a variety of organ systems
thought to play key roles in blood pressure homeostasis,
including the heart, kidney, blood vessels, adrenal glands, and
cardiovascular control centers in the brain (13). For example,
in the vascular system, stimulation of AT1 receptors causes
potent vasoconstriction (14, 15). In the adrenal cortex, their
activation stimulates the release of aldosterone (16) that in
turn promotes sodium reabsorption in the mineralocorticoid-
responsive segments of the distal nephron (17). In the brain,
intraventricular injection of Ang II causes a dramatic pressor
response that is mediated by AT1A receptors (18). In the
kidney, activation of AT1 receptors is associated with renal
vasoconstriction and antinatriuresis (19, 20). Nevertheless,
whether angiotensin actions in these individual tissue sites
contribute in vivo to the pathogenesis of hypertension and its
complications is not clear.
To address this question, we used a kidney cross-transplantation
strategy to separate the actions of AT1 receptor pools in the kidney
from those in systemic tissues. Our findings suggest that AT1
receptors expressed in the kidney are the primary determinants
of hypertension and end-organ damage in Ang II-dependent
hypertension.
Results
Kidney Cross-Transplantation Model. We used a kidney cross-
transplantation strategy to separate the actions of AT1 receptor
pools in the kidney from those in systemic tissues, as we have
described previously (21). Kidney transplantation was carried out
between genetically matched F1(C57BL6  129) wild-type mice
and F1(C57BL6  129) mice homozygous for a targeted disrup-
tion of the Agtr1a gene locus encoding the AT1A receptor (14). The
AT1A receptor is the major AT1 receptor isoform in the mouse and
the closest mouse homologue to the human AT1 receptor gene (12).
By varying the genotype of the transplant donor and recipient, we
generated four groups of animals in which renal function was
provided entirely by the single transplanted kidney. The Wild-type
group consisted of wild-type mice transplanted with kidneys from
wild-type donors and thus have normal expression of AT1A recep-
tors in the kidney transplant and in all systemic tissues. For the
Systemic KO group, AT1A receptor-deficient recipients were trans-
planted with kidneys from wild-type donors; these animals lack
AT1A receptors in all tissues except the kidney. Kidney KO animals
are wild-type recipients of AT1A receptor-deficient kidneys, thus
lacking expression of AT1A receptors only in the kidney, but with
normal expression of receptors in all systemic, nonrenal tissues,
including the adrenal gland. Finally, the Total KO group consists of
AT1A receptor-deficient recipients of AT1A receptor-deficient kid-
neys and therefore completely lacking AT1A receptors in all tissues.
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Baseline Blood Pressure Measurements. One week after the trans-
plantation procedure, radiotelemetry transmitters were implanted
to provide direct measurements of arterial pressures in the mice in
a conscious and unrestrained state. One week after placement of
these units, when the animals had regained normal diurnal variation
of blood pressure, blood pressure measurement was initiated.
Baseline blood pressures in the Systemic KO and Kidney KO groups
were virtually identical [109  1 mmHg vs. 109  1 mmHg (1
mmHg  133 Pa)] and intermediate to those of the Wild-type
(114  2 mmHg) and Total KO (97  2 mmHg) groups, consistent
with our previous experiments (21) showing that renal and systemic
AT1 receptors make equivalent contributions to the level of blood
pressure in the basal state.
A Major Role for AT1 Receptors in the Kidney in Ang II-Dependent
Hypertension. To distinguish the AT1 receptor population that is
critical for the pathogenesis of hypertension, osmotic minipumps
were implanted s.c. into each animal to infuse Ang II (1,000
ngkgmin) continuously for 4 weeks. This is a widely used model
of experimental hypertension in which elevated blood pressure is
mediated by ligand stimulation of AT1 receptors causing significant
end-organ damage, including cardiac hypertrophy (22–24). Upon
initiation of Ang II infusion, mean arterial pressures (MAP) in the
Wild-type transplant group rose dramatically to almost 160 mmHg
(Fig. 1A) and remained elevated throughout the infusion period
(MAP of 166  3 mmHg for Week 3 of infusion; mean BP increase
of  55  3 mmHg). This degree of blood pressure increase is
similar to that seen in previous studies using nontransplanted mice
(23), suggesting that the transplant procedure and the presence of
only a single kidney does not significantly alter blood pressure
responses to chronic Ang II infusion. By contrast, blood pressures
in the Total KO animals that are completely devoid of AT1A
receptors were affected only minimally by Ang II infusion (Fig. 1A),
reflecting the key role of AT1 receptors in the development of
hypertension in this model (MAP of 104  3 mmHg at Week 3).
The modest ( 6  3 mmHg; P  0.05) increase in blood pressure
in these animals was likely mediated by expression of the minor AT1
receptor isoform, AT1B, which is unaffected by the AT1A gene
disruption (15).
The Kidney KO animals (Fig. 1A) experienced an immediate
increase in blood pressure when the Ang II infusion was initiated,
peaking on Day 2 (135  5 mmHg; P  0.0003 vs. Kidney KO
baseline) and rapidly receding thereafter. However, at every time
point, including Day 2, blood pressures in the Kidney KOs were
significantly lower than those in the Wild-type group. Accordingly,
the degree of hypertension was markedly attenuated in the Kidney
KOs compared with the Wild-type group (MAP of 126  5 vs. 166 
3 mmHg at Week 3; P  0.0001). Moreover, the extent of the blood
pressure increase in the Kidney KO group was not different from
that seen in the Total KOs ( 15  4 mmHg; P  NS vs. Total KO).
Despite the early and transient increase in blood pressure, presum-
ably due to peripheral vasoconstriction, the absence of AT1A
receptors in the kidney alone is sufficient to protect from Ang
II-dependent hypertension.
In contrast, in the Systemic KO animals expressing AT1A recep-
tors only in the kidney (Fig. 1A), MAP rose progressively over the
first 2 weeks of Ang II infusion. Yet, their blood pressures lagged
behind the higher pressures seen in the Wild-type group for the first
10 days, likely reflecting the transient contribution of the early
vasoconstrictor response seen in the Kidney KOs. Nonetheless, from
Day 4 onward, blood pressures in Systemic KOs significantly ex-
ceeded those of the Kidney KOs (P  0.008). Furthermore, by Day
12, blood pressures in the Systemic KOs converged with and were
virtually identical to those of the Wild-type group (161  5 mmHg
for Week 3; mean BP increase of  51  4 mmHg; P  NS vs.
Wild-type; P  0.0003 vs. Kidney KO). Accordingly, the presence of
AT1A receptors in the kidney alone is sufficient to recapitulate the
hypertension phenotype of the Wild-type group. Together, these
data show that Ang II causes hypertension primarily through AT1A
receptors expressed in the kidney.
Urinary Sodium Excretion. We reasoned that activation of AT1
receptors in the kidney might cause hypertension by influencing
renal sodium handling (2). Therefore, we compared urinary sodium
excretion between the experimental groups during the first week of
Ang II infusion. The animals were placed in metabolic cages (25),
and food and water intakes were matched to avoid confounding
effects of variable intake on urinary electrolyte excretion. Before
implantation of Ang II-infusion pumps, total urinary sodium ex-
cretion (UNaV) was similar in the four experimental groups (not
shown). In contrast, cumulative sodium excretion measured during
the first 5 days of Ang II infusion (Fig. 1B) was significantly reduced
in the hypertensive Wild-type and Systemic KO groups compared
with the Kidney KO and Total KO groups. The latter two groups lack
AT1A receptors in the kidney and are resistant to the hypertensive
actions of Ang II (Fig. 1A).
Impaired sodium excretion by the kidney may increase blood
pressure by expanding intravascular fluid volume (2), which should
be reflected acutely by changes in body weight. Therefore, to
determine whether the reduced sodium excretion in the Wild-type
and Systemic KO groups led to volume expansion, we compared
Fig. 1. Blood pressures and urinary sodium excretion in mice after kidney
cross-transplantation. (A) Daily, 24-h blood pressures in the experimental
groups before (‘‘pre’’) and during 21 days of Ang II infusion (*, P  0.03 vs.
Wild-type; §, P  0.008 vs. Systemic KO; †, P  0.006–0.0001 vs. Wild-type). (B)
Cumulative sodium excretion during the first 5 days of Ang II infusion. (§, P 
0.02 vs. Kidney KO and P  0.03 vs. Total KO; ‡, P  0.03 vs. Kidney KO and Total
KO). (C) Change in body weights after 5 days of Ang II infusion. (*, P  0.03 vs.
‘‘pre’’; #, P  0.05 vs. ‘‘pre’’).
17986  www.pnas.orgcgidoi10.1073pnas.0605545103 Crowley et al.
body weights at baseline and after 5 days of Ang II infusion. Body
weights increased significantly in the Wild-type ( 5.9%) and
Systemic KO ( 4.2%) groups but did not change significantly in the
Kidney KO and Total KO groups (Fig. 1C), exactly paralleling the
effects of Ang II on sodium excretion. These data indicate that Ang
II causes hypertension by activating AT1 receptors in the kidney
promoting sodium reabsorption. Conversely, when AT1 receptors
in the kidney are absent, sufficient sodium is excreted in the urine
to protect against the development of hypertension. These findings
suggest that ACE inhibitors and ARBs reduce blood pressure in
hypertensive patients by attenuating AT1 receptor signals in the
kidney, thereby facilitating excretion of sodium.
Cardiac Hypertrophy Depends on Blood Pressure Elevation Rather
Than Expression of AT1 Receptors in the Heart. In patients with
hypertension, one of the early and most common consequences of
chronic hypertension is left ventricular hypertrophy (LVH), and the
presence of LVH is associated with significant cardiovascular risk
(26, 27). Clinical evidence suggests that the RAS contributes to the
development of LVH in hypertension (28–30). In our experiments,
Systemic KO animals develop severe hypertension but lack AT1A
receptors in the heart. Conversely, Kidney KO animals are resistant
to Ang II-induced hypertension but have a full complement of
cardiac AT1A receptors. Thus, we reasoned that we could use our
model to separate the effects of elevated blood pressure from direct
cellular actions of AT1 receptors in the development of cardiac
hypertrophy.
Accordingly, we compared heart size in the four experimental
groups. With Ang II infusion, the Wild-type group developed robust
cardiac hypertrophy (Fig. 2 A, E, and I), the extent of which was
similar to that of previous studies with intact Wild-type animals
infused with Ang II (23). In the Systemic KO group, which develop
hypertension but lack AT1A receptors in the heart, the degree of
cardiac hypertrophy and increased left ventricular wall thickness
was similar to that in the Wild-type group (Fig. 2 B, F, and I),
indicating that cardiac AT1 receptors are not necessary for the
development of hypertrophy in this model. In contrast, in the Kidney
KO group, with the normal complement of cardiac AT1A receptors
but without hypertension, there was no evidence of hypertrophy
after Ang II infusion (Fig. 2 C, G, and I). Moreover, heart sizes and
weights in the Kidney KO group were virtually identical to those of
the Total KO group (Fig. 2 D, H, and I). These results suggest that
prolonged stimulation of AT1 receptors in the heart, without blood
pressure elevation, is not sufficient to cause cardiac hypertrophy in
vivo. As shown in Fig. 3J, there was a tight correlation between heart
Fig. 2. Cardiac hypertrophy with angiotensin II infusion. (A–H) Representa-
tive hearts and left ventricular cross-sections after 28 days of Ang II infusion:
A and E, Wild-type; B and F, Systemic KO; C and G, Kidney KO; D and H, Total
KO. (I) Mean heart-to-body weight ratios after 28 days of Ang II infusion. The
dashed line represents the mean heart-to-body weight ratio for noninfused
Wild-type mice established in previous experiments in our laboratory (23).
Wild-type and Systemic KO groups exhibit significant cardiac hypertrophy.
(n  9 per group; §, P  0.002 vs. Kidney KO and P  0.0004 vs. Total KO; ‡, P 
0.003 vs. Kidney KO and P  0.0008 vs. Total KO). (J) For the entire cohort, there
was a significant positive correlation between heart-to-body weight ratio and
blood pressure (R  0.84. P  0.0001).
Fig. 3. Cardiac injury after angiotensin II infusion. (A–D) Representative
photomicrographs of heart sections stained with Masson trichrome. (Magni-
fication: 20.) Vascular lesions with perivascular infiltrates, medial expansion,
and myocyte injury were common in hearts from the Wild-type (A) and
Systemic KO (B) groups, whereas myocardial and vascular morphology were
normal in the Kidney KO (C) and Total KO (D) groups. (E) Semiquantitative
scoring of cardiac pathology (§, P  0.002 vs. Kidney KO and P  0.0003 vs.
Total KO; ‡, P  0.02 vs. Kidney KO and P  0.004 vs. Total KO).







weight and blood pressure across all four experimental groups,
suggesting that cardiac hypertrophy depends primarily on the level
of blood pressure rather than the presence of AT1 receptors in the
heart.
Cardiac Pathology with Ang II Hypertension. We next examined the
extent of cardiac histopathology in the four experimental groups.
Sections from the Wild-type and Systemic KO groups showed
significant and similar degrees of pathology (Fig. 3 A and B),
including perivascular cellular infiltrates, vessel wall thickening, and
myocardial injury. In contrast, vessel wall structure and myocardial
architecture were normal in the Kidney KO sections (Fig. 3C) and
virtually indistinguishable from the Total KO hearts (Fig. 3D). With
quantitative scoring (Fig. 3E), the two groups with hypertension
(Wild-type and Systemic KO) displayed significant cardiac injury
whether or not AT1A receptors were expressed in the heart, whereas
cardiac injury was minimal in the Kidney KO group despite their
normal expression of cardiac AT1A receptors.
Cardiac Gene Expression Patterns During Ang II Hypertension. Al-
though our evaluations of heart weight and histology indicate a
dominant effect of blood pressure on cardiac pathology, we con-
sidered the possibility that these assessments might not be suffi-
ciently sensitive to detect cellular actions of AT1 receptors in cardiac
myocytes. During hypertrophic cardiac remodeling, gene expres-
sion in myocardium undergoes characteristic alterations, including
enhanced expression of atrial natriuretic peptide (ANP) and brain
natriuretic peptide (BNP), along with recapitulation of fetal gene
expression patterns for myosin heavy chains (MHC) characterized
by a down-regulation of -MHC and up-regulation of the -MHC
isoform (31–34). Previous studies have suggested that Ang II may
stimulate these processes (35, 36). We therefore examined cardiac
mRNA expression for ANP, BNP, -MHC, and -MHC after 4
weeks of Ang II infusion. As shown in Fig. 4A, levels of mRNA for
both ANP and BNP were both dramatically increased in hearts
from Wild-type animals compared with hearts from the Total KO
group. Expression was similarly enhanced in the Systemic KO group
despite their lack of cardiac AT1A receptors. In contrast, up-
regulation of ANP or BNP mRNAs was not detected in the Kidney
KO hearts despite their full complement of cardiac AT1A receptors.
A similar pattern was observed in our measurements of -MHC
and -MHC mRNA levels. As depicted in Fig. 4B, the ratio of
-MHC-MHC expression was increased by nearly 4-fold in the
Wild-type and Systemic KO groups compared with the Kidney KO
and Total KO groups.
Discussion
A major role for the RAS in promoting hypertension and its
associated end-organ damage has long been recognized (37–39).
These actions are mediated primarily by AT1 receptors (30, 40).
Expression of AT1 receptors in key sites involved in regulation of
peripheral vascular resistance, sodium balance, and activity of the
sympathetic nervous system is also consistent with its critical role in
blood pressure homeostasis. Because pharmacological antagonists
and conventional gene knockouts produce global inhibition of AT1
receptors, it has been difficult to discriminate clearly which of these
specific tissue sites mediate the pathogenic actions of AT1 receptors
in hypertension. Accordingly, we developed an experimental model
of kidney cross-transplantation in the mouse that allows for sepa-
ration of AT1 receptor pools in the kidney from those in other
tissues.
A major finding in our study is that AT1 receptors in the kidney
are primarily responsible for the actions of Ang II to cause
hypertension. This is clearly illustrated in the Systemic KO animals,
where the presence of AT1A receptors only in the kidney is sufficient
to recapitulate the phenotyope of hypertension with Ang II infu-
sion. Conversely, in the Kidney KO group, the absence of AT1
receptors from the kidney alone is sufficient to protect these
animals from Ang II-dependent hypertension, despite the expres-
sion of AT1A receptors in a number of other key areas that
potentially impact blood pressure homeostasis, including the brain,
the heart, the peripheral vasculature, and the adrenal gland. The
mechanism for the distinct blood pressure responses in the two
groups appears to be related to differences in renal sodium han-
dling. Ang II infusion is associated with reduced renal sodium
excretion and weight gain in the Systemic KO group, whereas the
absence of renal AT1 receptors in the Kidney KOs is associated with
enhanced natriuresis, no change in weight, and resistance to hy-
pertension. It is important that these effects on blood pressure and
sodium excretion are determined by direct actions of AT1 receptors
within the kidney, independent of any contribution of Ang II-
dependent aldosterone release.
Within the kidney, AT1 receptors are expressed on epithelial cells
throughout the nephron, in the glomerulus, and on the renal
vasculature (41, 42). In the proximal tubule, AT1 receptors promote
sodium reabsorption by coordinately stimulating the sodium-
proton antiporter on the luminal membrane along with the sodium-
potassium ATPase on the basolateral surface (43, 44). AT1 recep-
tors also affect sodium reabsorption in distal nephron segments,
including the thick ascending limb, distal tubule, and collecting duct
(45–48). In the collecting duct, for example, Bell and associates
have shown that Ang II directly stimulates epithelial sodium
channel activity through an AT1 receptor-dependent mechanism
(49). AT1 receptors expressed in the renal vasculature also have
important regulatory effects on sodium handling (50). Renal va-
soconstriction caused by Ang II, which we have previously shown
to be primarily mediated by AT1A receptors (51), reduces medullary
blood flow, blunting the kidney’s excretory capacity for sodium (52,
53). Our study suggests that the primary mechanism of action of
ACE inhibitors and ARBs to reduce blood pressure in hypertensive
patients is attenuation of AT1 receptor signals at one or more of
these key sites in the kidney.
In previous work focused on normal blood pressure homeostasis,
we found that AT1 receptor actions in the kidney and extrarenal
Fig. 4. Cardiac gene expression in mice infused with angiotensin II. (A)
Expression of ANP and BNP mRNA in hearts (n  8 per group; §, P  0.003 vs.
Kidney KO and P  0.002 vs. Total KO; ‡, P  0.004 vs. Kidney KO and P  0.003
vs. Total KO; *, P  0.02 vs. Kidney KO and P  0.002 vs. Total KO; #, P  0.01
vs. Kidney KO and P  0.002 vs. Total KO). (B) Ratio of cardiac -MHC-to--
MHC mRNA expression in hearts. (§, P  0.01 vs. Kidney KO and P  0.03 vs.
Total KO; ‡, P  0.002 vs. Kidney KO and P  0.01 vs. Total KO).
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tissues made virtually equivalent contributions to preventing hypo-
tension and supporting normal blood pressure (21). Thus, when
circulatory volumes are threatened, the full range of AT1 receptor
actions at key tissue sites is activated and apparently necessary to
protect against circulatory collapse. On the other hand, their
relative contributions appear to be quite different in hypertension
where the population of AT1 receptors in the kidney assumes a
preeminent role. In this regard, Guyton hypothesized that the
substantial capacity for sodium excretion by the kidney provides a
compensatory system of virtually infinite gain to oppose processes,
including increases in peripheral vascular resistance, which would
tend to increase blood pressure (2). It follows that defects in renal
excretory function would be a prerequisite, therefore, for sustaining
a chronic increase in intra-arterial pressure. Our current findings
confirm the key role of altered renal sodium handling in Ang
II-dependent hypertension and are completely consistent with
Guyton’s hypothesis.
There was a statistically significant increase in blood pressure in
the Kidney KO group coinciding with the initiation of the angio-
tensin II infusion. This increase in blood pressure rapidly peaked on
Day 2 and then gradually returned toward baseline. We speculate
that this early change in blood pressure was due to vasoconstriction
mediated by AT1 receptors in the peripheral vasculature. Its rapid
attenuation was likely due to the accompanying natriuresis. This
pattern illustrates the relatively modest contribution of systemic
vasoconstriction, in isolation, to the development of Ang II-
dependent hypertension. Even at their peak, blood pressures in the
Kidney KOs remained substantially lower than those in the Wild-type
group. Furthermore, blood pressures in this group were consistently
and substantially reduced compared with those of the Systemic KOs.
Thus, chronic systemic vasoconstriction driven by Ang II has a very
limited capacity to cause sustained hypertension.
The pattern in the Systemic KO group was quite different. Blood
pressure increased progressively during the first 2 weeks, although
the rate of rise was delayed compared with that of the Wild-type
group. We suggest that this early difference reflects the absence of
the transient vasoconstrictor response seen in the Kidney KOs. With
time, however, pressures in the Systemic KOs eventually reach the
level of the Wild-type group, indicating that AT1 receptor actions in
the kidney are sufficient to generate the full hypertension pheno-
type. Moreover, as discussed below, the similar extent of cardiac
hypertrophy seen in the Wild-type and Systemic KO groups, and its
complete absence in the Kidney KO group, suggests that the late,
sustained phase of hypertension provides the major stimulus for
end-organ injury in this model.
A major goal of hypertension treatment is to prevent or ame-
liorate injury to key target organs, including the heart, kidney, and
brain. One of the most prevalent manifestations of end-organ
damage in hypertension is the development of LVH (26), and its
presence confers substantial cardiovascular risk (26, 27). Although
pressure load from elevated blood pressure clearly contributes to
LVH, several lines of evidence suggest that activation of the RAS
also plays a role. For example, Ang II, acting through AT1 receptors,
stimulates hypertrophy of cardiac myocytes in culture (54, 55). In
addition, clinical studies have demonstrated actions of ACE inhib-
itors and ARBs to cause regression of LVH more effectively than
other classes of antihypertensive agents with similar levels of blood
pressure control (28–30).
Although distinguishing the relative contributions of hyperten-
sion and cardiac AT1 receptor activation to the development of
LVH in vivo has been difficult, we reasoned that our model might
be useful for this purpose. The extent of blood pressure elevation
was very similar in the Wild-type and Systemic KO groups, but they
differ in their expression of AT1A receptors in the heart. Despite
lacking cardiac AT1A receptors, the Systemic KO group developed
robust LVH with heart weights that were not significantly different
from those of the Wild-type group. By contrast, Kidney KOs with a
normal complement of cardiac AT1A receptors do not develop
significant hypertension and likewise have no appreciable change in
their heart weights. Within the entire cohort, there was a tight linear
correlation between heart weight and blood pressure irrespective of
the presence or absence cardiac AT1A receptors. Thus, in a simple
model of Ang II-dependent hypertension, the severity of cardiac
hypertrophy was exclusively dependent on blood pressure. We
found no evidence for a contribution of direct actions of AT1
receptors in the heart to promote LVH. Although our data are
clear-cut, they do not necessarily obviate the results of well-designed
prospective clinical trials demonstrating beneficial effects of ACE
inhibitors or ARBs on regression of LVH (29, 30). Rather, they
suggest that the benefits of these agents in LVH are not a conse-
quence of blocking cellular actions of Ang II in the heart, but may
be due to differences in the degree or pattern of blood pressure
control that was achieved (56).
Direct effects of AT1 receptor activation to promote inflamma-
tion, fibrosis, and vascular damage have been implicated as path-
ways for facilitating end-organ damage in hypertension (22, 24,
57–61). In our studies, we found that Ang II infusion caused cardiac
fibrosis and vascular pathology in the Wild-type and Systemic KO
groups. On the other hand, hearts in the Kidney KOs appeared
virtually normal, indicating that vascular injury and fibrosis in the
heart were also consequences of elevated blood pressure rather
than local actions of cardiac AT1 receptors. Cardiac hypertrophy is
associated with characteristic alterations in gene expression, includ-
ing up-regulation of ANP and BNP (31, 32), and recapitulation of
fetal patterns for expression of myosin heavy chains (33, 34). It has
been suggested that activation of AT1 receptors in cardiomyocytes
may be sufficient to trigger this transcription profile (34, 35).
However, as we observed with cardiac hypertrophy and pathology,
activation of AT1 receptors in the heart is not responsible for
characteristic gene expression patterns associated with Ang II
infusion; these are also triggered by elevated blood pressure.
In summary, these studies provide incontrovertible evidence that
angiotensin II causes hypertension through actions of AT1 receptors
expressed in the kidney that reduce urinary sodium excretion. This
is a direct effect of AT1 receptors in the kidney that does not involve
or require angiotensin II-mediated aldosterone responses in the
adrenal gland. Our findings suggest that the mechanism of antihy-
pertensive actions of ACE inhibitors and ARBs involves attenua-
tion of the renal actions of angiotensin II. Furthermore, these
experiments indicate that the major mechanism of protection from
cardiac hypertrophy afforded by these agents is related to blood
pressure control rather than inhibition of AT1 receptor actions in
the heart.
Materials and Methods
Animals. (129  C57BL6)F1 mice lacking AT1A receptors for Ang
II were generated as described in ref. 14. Animals were bred and
maintained in the animal facility of the Durham Veterans Affairs
Medical Center under National Institutes of Health guidelines.
These studies used 2- to 4-month-old male mice.
Mouse Kidney Transplantation. Vascularized kidney transplants
were performed in mice as described in ref. 21. The donor kidney,
ureter, and bladder were harvested en bloc, including the renal
artery with a small aortic cuff and the renal vein with a small vena
caval cuff. These vascular cuffs were anastomosed to the recipient
abdominal aorta and vena cava, respectively, below the level of the
native renal vessels. Donor and recipient bladders were attached
dome to dome. The right native kidney was removed at the time of
transplant, and the left native kidney was removed through a flank
incision 1–3 days later. The adrenal glands and their blood supply
were preserved intact. Each group consisted of at least seven
animals.
Telemetry Probe Implantation Procedure. The components of the
radiotelemetry system (Transoma Medical, St. Paul, MN), includ-







ing the mouse blood pressure telemetry device (TA11PA-C20), are
described in ref. 62. Six to 8 days after the kidney transplantation
procedure, the pressure catheter was implanted in the left carotid
artery as described in ref. 63.
Telemetric Blood Pressure Analysis. Data were collected, stored, and
analyzed by using Dataquest A.R.T. software (Transoma Medical).
Blood pressures were measured on unanesthetized, unrestrained
animals beginning 7 days after the catheter implantation when the
mice had reestablished normal circadian rhythms (63). Telemetry
data were collected continuously with sampling every 6 min for 10-s
intervals (62).
Experimental Protocol. Baseline blood pressure measurements were
determined on 3 consecutive days while the animals ingested a
normal diet containing 0.4% sodium chloride. After these baseline
recordings, an osmotic minipump (Alzet Model 2004; DURECT)
infusing Ang II (Sigma, St. Louis, MO) at a rate of 1,000 ngkgmin
was implanted s.c. as described in ref. 23, and blood pressure
measurements continued for 21 days.
Metabolic Balance Studies. One week after transplantation, the
animals were placed in specially designed metabolic cages (23). The
mice were fed 10 gmday gelled 0.25% NaCl diet that contained all
nutrients and water (Nutra-gel; Bio-Serv, Frenchtown, NJ). After
1 week of baseline collections, the animals were implanted with
osmotic minipumps infusing Ang II as described above and were
returned to the metabolic cage for 5 more days. Urinary sodium
content was determined by using an IL943 Automatic Flame
photometer per the manufacturer’s instructions (Instrumentation
Laboratory, Lexington, MA).
Histopathologic Analysis. After 28 days of Ang II infusion, hearts
were harvested, weighed, fixed in formalin, sectioned, and stained
with Masson trichrome. All of the tissues were examined by a
pathologist (P.R.) without knowledge of genotypes. Pathology was
graded based on the presence and severity of component abnor-
malities, including cellular infiltrate, myocardial cell injury, vessel
wall thickening, and fibrosis. Grading for each component was
performed by using a semiquantitative scale where 0 was normal
and 1–4 represented mild through severe abnormalities. The total
cardiac injury score for each heart was a summation of the
component injury scores.
Quantification of Cardiac mRNA Expression. Hearts were harvested,
and total RNA was isolated by using an RNeasy mini kit per the
manufacturer’s instructions (Qiagen, Valencia, CA). The gene
expression levels of ANP, BNP, -MHC, and -MHC in cardiac
tissue were determined by real-time quantitative RT-PCR as
reported in ref. 64.
Statistical Analysis. The values for each parameter within a group
are expressed as the mean  SEM. For comparisons between
groups with normally distributed data, statistical significance was
assessed by using ANOVA followed by an unpaired t test; within
groups, a paired t test was used. For nonparametric comparisons,
the Mann–Whitney U test was used between groups, and the
Wilcoxon signed rank test was used within groups.
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